207 related articles for article (PubMed ID: 24700612)
21. Perlecan-deficient mutation impairs corneal epithelial structure.
Inomata T; Ebihara N; Funaki T; Matsuda A; Watanabe Y; Ning L; Xu Z; Murakami A; Arikawa-Hirasawa E
Invest Ophthalmol Vis Sci; 2012 Mar; 53(3):1277-84. PubMed ID: 22266517
[TBL] [Abstract][Full Text] [Related]
22. Evolution of the perlecan/HSPG2 gene and its activation in regenerating Nematostella vectensis.
Warren CR; Kassir E; Spurlin J; Martinez J; Putnam NH; Farach-Carson MC
PLoS One; 2015; 10(4):e0124578. PubMed ID: 25876075
[TBL] [Abstract][Full Text] [Related]
23. TGFβ1 alters androgenic metabolites and hydroxysteroid dehydrogenase enzyme expression in human prostate reactive stromal primary cells: Is steroid metabolism altered by prostate reactive stromal microenvironment?
Piao YS; Wiesenfeld P; Sprando R; Arnold JT
J Steroid Biochem Mol Biol; 2013 Nov; 138():206-13. PubMed ID: 23770322
[TBL] [Abstract][Full Text] [Related]
24. Impaired angiogenesis, delayed wound healing and retarded tumor growth in perlecan heparan sulfate-deficient mice.
Zhou Z; Wang J; Cao R; Morita H; Soininen R; Chan KM; Liu B; Cao Y; Tryggvason K
Cancer Res; 2004 Jul; 64(14):4699-702. PubMed ID: 15256433
[TBL] [Abstract][Full Text] [Related]
25. Heparan sulfate of perlecan is involved in glomerular filtration.
Morita H; Yoshimura A; Inui K; Ideura T; Watanabe H; Wang L; Soininen R; Tryggvason K
J Am Soc Nephrol; 2005 Jun; 16(6):1703-10. PubMed ID: 15872080
[TBL] [Abstract][Full Text] [Related]
26. Perlecan is essential for cartilage and cephalic development.
Arikawa-Hirasawa E; Watanabe H; Takami H; Hassell JR; Yamada Y
Nat Genet; 1999 Nov; 23(3):354-8. PubMed ID: 10545953
[TBL] [Abstract][Full Text] [Related]
27. Primary structure of the human heparan sulfate proteoglycan from basement membrane (HSPG2/perlecan). A chimeric molecule with multiple domains homologous to the low density lipoprotein receptor, laminin, neural cell adhesion molecules, and epidermal growth factor.
Murdoch AD; Dodge GR; Cohen I; Tuan RS; Iozzo RV
J Biol Chem; 1992 Apr; 267(12):8544-57. PubMed ID: 1569102
[TBL] [Abstract][Full Text] [Related]
28. Heparan sulfate in perlecan promotes mouse atherosclerosis: roles in lipid permeability, lipid retention, and smooth muscle cell proliferation.
Tran-Lundmark K; Tran PK; Paulsson-Berne G; Fridén V; Soininen R; Tryggvason K; Wight TN; Kinsella MG; Borén J; Hedin U
Circ Res; 2008 Jul; 103(1):43-52. PubMed ID: 18596265
[TBL] [Abstract][Full Text] [Related]
29. Perlecan heparan sulfate proteoglycan is a critical determinant of angiogenesis in response to mouse hind-limb ischemia.
Qiang B; Lim SY; Lekas M; Kuliszewski MA; Wolff R; Osherov AB; Rudenko D; Leong-Poi H; Noyan H; Husain M; Tran K; Tryggvason K; Hedin U; Tran-Lundmark K; Strauss BH
Can J Cardiol; 2014 Nov; 30(11):1444-51. PubMed ID: 25249499
[TBL] [Abstract][Full Text] [Related]
30. Perlecan heparan sulfate deficiency impairs pulmonary vascular development and attenuates hypoxic pulmonary hypertension.
Chang YT; Tseng CN; Tannenberg P; Eriksson L; Yuan K; de Jesus Perez VA; Lundberg J; Lengquist M; Botusan IR; Catrina SB; Tran PK; Hedin U; Tran-Lundmark K
Cardiovasc Res; 2015 Jul; 107(1):20-31. PubMed ID: 25952902
[TBL] [Abstract][Full Text] [Related]
31. An association study of a polymorphism in the heparan sulfate proteoglycan gene (perlecan, HSPG2) and Alzheimer's disease.
Rosenmann H; Meiner Z; Kahana E; Aladjem Z; Friedman G; Ben-Yehuda A; Grenader T; Wertman E; Abramsky O
Am J Med Genet B Neuropsychiatr Genet; 2004 Jul; 128B(1):123-5. PubMed ID: 15211644
[TBL] [Abstract][Full Text] [Related]
32. Spectrum of HSPG2 (Perlecan) mutations in patients with Schwartz-Jampel syndrome.
Stum M; Davoine CS; Vicart S; Guillot-Noël L; Topaloglu H; Carod-Artal FJ; Kayserili H; Hentati F; Merlini L; Urtizberea JA; Hammouda el-H; Quan PC; Fontaine B; Nicole S
Hum Mutat; 2006 Nov; 27(11):1082-91. PubMed ID: 16927315
[TBL] [Abstract][Full Text] [Related]
33. Perlecan knockdown in metastatic prostate cancer cells reduces heparin-binding growth factor responses in vitro and tumor growth in vivo.
Savorè C; Zhang C; Muir C; Liu R; Wyrwa J; Shu J; Zhau HE; Chung LW; Carson DD; Farach-Carson MC
Clin Exp Metastasis; 2005; 22(5):377-90. PubMed ID: 16283481
[TBL] [Abstract][Full Text] [Related]
34. Synovial perlecan is required for osteophyte formation in knee osteoarthritis.
Kaneko H; Ishijima M; Futami I; Tomikawa-Ichikawa N; Kosaki K; Sadatsuki R; Yamada Y; Kurosawa H; Kaneko K; Arikawa-Hirasawa E
Matrix Biol; 2013 Apr; 32(3-4):178-87. PubMed ID: 23339896
[TBL] [Abstract][Full Text] [Related]
35. HSPG2 overexpression independently predicts poor survival in patients with acute myeloid leukemia.
Zhou X; Liang S; Zhan Q; Yang L; Chi J; Wang L
Cell Death Dis; 2020 Jun; 11(6):492. PubMed ID: 32606327
[TBL] [Abstract][Full Text] [Related]
36. Cleavage of the Perlecan-Semaphorin 3A-Plexin A1-Neuropilin-1 (PSPN) Complex by Matrix Metalloproteinase 7/Matrilysin Triggers Prostate Cancer Cell Dyscohesion and Migration.
Tellman TV; Cruz LA; Grindel BJ; Farach-Carson MC
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33809984
[TBL] [Abstract][Full Text] [Related]
37. Co-operative functions between nuclear factors NFkappaB and CCAT/enhancer-binding protein-beta (C/EBP-beta) regulate the IL-6 promoter in autocrine human prostate cancer cells.
Xiao W; Hodge DR; Wang L; Yang X; Zhang X; Farrar WL
Prostate; 2004 Dec; 61(4):354-70. PubMed ID: 15389813
[TBL] [Abstract][Full Text] [Related]
38. Discovery of HSPG2 (Perlecan) as a Therapeutic Target in Triple Negative Breast Cancer.
Kalscheuer S; Khanna V; Kim H; Li S; Sachdev D; DeCarlo A; Yang D; Panyam J
Sci Rep; 2019 Aug; 9(1):12492. PubMed ID: 31462656
[TBL] [Abstract][Full Text] [Related]
39. Expression and Circulating Levels of Perlecan in Breast Cancer - Implications for Oestrogen Dependent Stromal Remodeling.
Jansson M; Billing O; Herdenberg C; Lundin C; Tolockiene E; Nazemroaya A; Sund M
J Mammary Gland Biol Neoplasia; 2020 Mar; 25(1):69-77. PubMed ID: 32124140
[TBL] [Abstract][Full Text] [Related]
40. Perlecan deficiency causes muscle hypertrophy, a decrease in myostatin expression, and changes in muscle fiber composition.
Xu Z; Ichikawa N; Kosaki K; Yamada Y; Sasaki T; Sakai LY; Kurosawa H; Hattori N; Arikawa-Hirasawa E
Matrix Biol; 2010 Jul; 29(6):461-70. PubMed ID: 20541011
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
